Please, Signup (Login) to subscribe or trade (demo)
Amgen Inc. stock price
Amgen Inc. latest news:
Apple and Alphabet skid while Amgen and Edwards jump
Apple and Alphabet slide while Amgen and Edwards Lifesciences advance
Apple and Alphabet skid while Amgen and Edwards jump
Stocks that moved substantially or traded heavily Friday: Apple Inc., down $7.41 to $160.37
Amgen shares drop 4% after Q4 profit, revenue misses
Amgen Inc. shares declined 4.3% after-hours on Thursday after the company reported fourth-quarter profit and revenue misses. The company reported a loss of $4.26 billion, or a loss of $5.89 per share, after earnings of $1.94 billion, or $2.59 per share in the year-earlier period. Adjusted earnings-per-share were $2.89, compared with the FactSet consensus of $3.03. The latest results include a $6.1 billion charge related to the U.S.'s corporate tax overhaul. Revenue declined to $5.80 billion from $5.97 billion, compared with the FactSet consensus of $5.85 billion. Sales of Neulasta, Enbrel, Prolia, Epogen, Kyprolis, Nplate and Neupogen beat the FactSet consensus, while sales of Repatha, Aranesp, Sensipar, Xgeva, Vectibix and Blincyto missed the consensus. Amgen expects 2018 revenue of $21.8 billion to $22.8 billion, compared with the FactSet consensus of $22.86 billion, and 2018 adjusted EPS of $12.60 to $13.70, compared with the FactSet consensus of $12.71. Amgen said its board also authorized $10 billion in share buybacks this month, in addition to the $4.4 billion in share buybacks from late last year.The company also touted plans for $3.5 billion in capital expenditures over the next five years, three-quarters of which is intended for the U.S., a 50% increase from recent years. It includes up to $300 million for a new U.S. manufacturing plant, which should employ about 220 individuals to build, and employ up to 300 skilled full-time employees, with a location finalized in the second quarter. Amgen shares have risen 5.8% over the last three months, compared with a 9.4% rise in the S&P 500 and a 11.5% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Amgen quarterly profit misses, 2018 EPS outlook ahead of Street view
Feb 1 (Reuters) - Amgen Inc on Thursday reported
fourth-quarter profit well below Wall Street estimates, as a
steep decline in sales of blockbuster rheumatoid arthritis drug
Enbrel and higher-than-expected expenses hit results.
BRIEF-Amgen Inc Q4 Loss Per Share $5.89
* AMGEN QTRLY LOSS PER SHARE $5.89; QTRLY ADJUSTED EARNINGS
SHARE $2.89; QTRLY REVENUE $5.80 BILLION, DOWN 3 PERCENT
BRIEF-Amgen Reports Aimovig Met All Primary, Secondary Endpoints
Amgen Inc(AMGN): * AMGEN REPORTS AIMOVIG MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS. * Amgen Inc (AMGN) - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE OF MAY 17, 2018.
BRIEF-European Commission Approves Amgen, Allergan's Mvasi
Amgen Inc(AMGN): * EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® FOR THE TREATMENT OF CERTAIN TYPES OF CANCER. * Amgen Inc (AMGN) - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI Source text for Eikon: Further company coverage:
BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label
Amgen Inc(AMGN): * FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLIS® LABEL. * Amgen Inc (AMGN) - U.S. FDA APPROVED SUPPLEMENTAL NEW DRUG APPLICATION TO ADD OVERALL SURVIVAL DATA FROM PHASE 3 TRIAL TO PRESCRIBING INFORMATION FOR KYPROLIS Source text for Eikon: Further company coverage:
BRIEF-Amgen says Analysis From Kyprolis Trial Published in Journal Of Clinical Oncology
Amgen Inc(AMGN): * OVERALL SURVIVAL ANALYSIS FROM KYPROLIS® PHASE 3 ASPIRE TRIAL PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Source text for Eikon: Further company coverage:
Amgen estimates its U.S. tax bill at over $6 billion as it repatriates cash
Amgen Inc(AMGN) said it expects to incur tax expenses of $6 billion to $6.5 billion over time as it repatriates cash it has accumulated around the world because of the new U.S. tax law signed by President Donald Trump on Friday. Some of the expense is also due to the revaluation of its tax liabilities, the drugmaker said in a filing with the Securities and Exchange Commission.
BRIEF-Amgen Announces 15 Percent Increase In Q1 2018 Dividend
Amgen Inc(AMGN): * AMGEN ANNOUNCES 15 PERCENT INCREASE IN 2018 FIRST QUARTER DIVIDEND. * SETS QUARTERLY DIVIDEND OF $1.32PER SHARE Source text for Eikon: Further company coverage:
Amgen raises dividend by 15% to $1.32 a share
Amgen late Tuesday announced that its board of directors declared a dividend of $1.32 a share for the first quarter of 2018. The dividend will be paid on March 8 to stockholders of record as of Feb. 15, the biotech company said. That's a 15% increase from the dividend paid in each of the previous four quarters, Amgen said. Shares of Amgen were flat in late trading after ending the regular session down 0.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients
Dec 11 (Reuters) - Amgen Inc said on Monday a final
analysis of late-stage trial data showed that its Kyprolis
combined with two other drugs helped blood cancer patients live
Amgen's Kyprolis improves overall survival in blood cancer patients
Dec 11 (Reuters) - Amgen Inc said on Monday new
data from a late-stage trial testing Kyprolis in combination
with two other drugs showed improved overall survival rate in
patients with blood cancer.
BRIEF-Xencor Receives Milestone Payment From Amgen
Xencor Inc(XNCR): * XENCOR RECEIVES MILESTONE PAYMENT FROM AMGEN. * SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN. * SAYS MILESTONE PAYMENT TRIGGERED BY SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AMG 424. * XENCOR RECEIVES MILESTONE PAYMENT FROM AMGEN Source text for Eikon: Further company coverage:
FDA approves heart protection claims for Amgen cholesterol drug
Dec 1 (Reuters) - Amgen Inc can now promote the
ability of its potent but expensive cholesterol drug to reduce
the risk of heart attacks and strokes, after U.S. health
regulators approved adding those benefits to the medicine's
prescribing label, the company said on Friday.
BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, ...
Amgen Inc(AMGN): * AIMOVIG PHASE 3 STRIVE DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE DEMONSTRATE SIGNIFICANT, SUSTAINED EFFICACY IN MIGRAINE PREVENTION Source text for Eikon: Further company coverage:
BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
* AIMOVIG™ (ERENUMAB) PHASE 3 STRIVE DATA PUBLISHED IN THE
ENGLAND JOURNAL OF MEDICINE DEMONSTRATE SIGNIFICANT, SUSTAINED
EFFICACY IN MIGRAINE PREVENTION
Source text for Eikon:
Further company coverage:
Amicus Therapeutics, Inc.FOLD
Amkor Technology, Inc.AMKR
Amphastar Pharmaceuticals, Inc.AMPH
Amtech Systems, Inc.ASYS
AmTrust Financial Services, Inc.AFSI
Anacor Pharmaceuticals, Inc.ANAC